ENXTAM:PHARMBiotechs
Pharming Group (ENXTAM:PHARM): Valuation Insights Following Raised 2025 Outlook and Strong Earnings Momentum
Pharming Group (ENXTAM:PHARM) just raised its revenue outlook for 2025 following an impressive earnings update, with sales up sharply and net loss narrowing year-over-year. Investors are taking note of this renewed momentum.
See our latest analysis for Pharming Group.
With a 44.7% year-to-date share price return and a striking 98% total shareholder return over the past year, Pharming Group’s strong results and refreshed leadership are building real momentum. Investors are rewarding the...